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ARTICLE
Type I interferon induces CXCL13 to support ectopic
germinal center formation
Alice E. Denton1, Silvia Innocentin1, Edward J. Carr1,2, Barry M. Bradford3, Fanny Lafouresse4,5, Neil A. Mabbott3, Urs Mo¨rbe6,
Burkhard Ludewig6, Joanna R. Groom4,5, Kim L. Good-Jacobson7,8, and Michelle A. Linterman1
Ectopic lymphoid structures form in a wide range of inflammatory conditions, including infection, autoimmune disease, and
cancer. In the context of infection, this response can be beneficial for the host: influenza A virus infection–induced pulmonary
ectopic germinal centers give rise to more broadly cross-reactive antibody responses, thereby generating cross-strain
protection. However, despite the ubiquity of ectopic lymphoid structures and their role in both health and disease, little is
known about the mechanisms by which inflammation is able to convert a peripheral tissue into one that resembles a secondary
lymphoid organ. Here, we show that type I IFN produced after viral infection can induce CXCL13 expression in a
phenotypically distinct population of lung fibroblasts, driving CXCR5-dependent recruitment of B cells and initiating ectopic
germinal center formation. This identifies type I IFN as a novel inducer of CXCL13, which, in combination with other stimuli, can
promote lung remodeling, converting a nonlymphoid tissue into one permissive to functional tertiary lymphoid structure
formation.
Introduction
Influenza A virus (IAV) causes respiratory infections that are a
significant cause of morbidity and mortality worldwide (Nair
et al., 2011; Somes et al., 2018). Current vaccines are an effec-
tive prophylactic treatment that limits infection before it takes
hold through the induction of strain-specific antibodies. How-
ever, what current influenza vaccines lack is the ability to
generate antibodies that are cross-protective between IAV
strains. It is known that tertiary lymphoid structures (TLSs),
which contain germinal centers (GCs), form in the lung after IAV
infection, and these pulmonary GCs are an effective way to
generate cross-protective humoral immunity (Adachi et al.,
2015). Typically, a GC forms in secondary lymphoid organs
(SLOs) after infection or immunization. It is a specialized mi-
croenvironment that generates long-term immunity through the
generation of memory B cells and antibody-secreting plasma
cells that are able to provide protection against subsequent in-
fection. A productive GC reaction requires the collaboration of
multiple cell types, including B cells, T follicular helper (Tfh)
cells, tingible body macrophages, and follicular dendritic cells
(FDCs; Vinuesa et al., 2016). Bringing these cells together re-
quires exquisite cellular coordination to ensure that the rare
antigen-specific T and B cells are able to interact with each other
in the right place and at the right time. The movement of im-
mune cells within the GC is coordinated by mesenchymal stro-
mal cell populations (Denton and Linterman, 2017); GC initiation
in SLOs requires fibroblastic reticular cells of the T cell zone
(Cremasco et al., 2014; Denton et al., 2014), and its maintenance
requires the FDC network within the B cell follicle (Wang et al.,
2011). Thus, the interactions between immune cells and stromal
cells are central to the formation of the GC and the quality of its
output. While vaccines typically induce GCs in SLOs, GCs can
also form within nonlymphoid tissues in response to infection
and inflammation. In the lung, infection, inhalation of particu-
late antigens, and pathological inflammation are known to in-
duce lymphocytic aggregates known as inducible bronchus-
associated lymphoid tissue (iBALT) that can form in the paren-
chyma (Moyron-Quiroz et al., 2004; Rangel-Moreno et al., 2006;
Foo and Phipps, 2010; Kuroda et al., 2016). These TLSs vary in
their cellular composition from loose clusters of T cells to highly
organized aggregates that contain GC-like structures (Moyron-
Quiroz et al., 2004; Foo and Phipps, 2010; Onodera et al., 2012;
Fleige et al., 2014). In the context of IAV infection, lung GCs
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confer protective immunity in the absence of SLO-derived re-
sponses (Moyron-Quiroz et al., 2004; Rangel-Moreno et al.,
2007) and with reduced immunopathology (Moyron-Quiroz
et al., 2004; Foo and Phipps, 2010; Onodera et al., 2012; Fleige
et al., 2014). Importantly, the output of lung GCs comprises
plasma cells and memory B cells with greater cross-protective
potential (Adachi et al., 2015), suggesting that the biology of lung
GCs is distinct from that of LN GCs.
Because ectopic GCs can generate these distinct broadly
neutralizing protective antibody responses, they represent an
interesting area for potential vaccine development. However,
despite the near-ubiquitous presence of ectopic GCs in multiple
inflammatory states (Pitzalis et al., 2014; Hwang et al., 2016), we
know surprisingly little about the mechanisms that drive their
formation and/or function, which limits the potential to use this
pathway therapeutically. Perhaps the simplest hypothesis is that
these ectopic GCs form in a way that is analogous to a nascent
LN, via conserved developmental pathways. Here, we show that
this is not the case and that a distinct mechanism initiates GCs in
the lung after IAV infection. Type I IFN produced in response to
infection induces expression of the chemokine C-X-C motif
ligand 13 (CXCL13) by lung fibroblasts. This drives C-X-C motif
receptor 5 (CXCR5)–dependent recruitment of B cells to the lung
to initiate the formation of functional GCs. This study establishes
that the early antiviral response initiates a cascade of signaling
events that act on local stromal cells to generate an environment
permissive to GC formation in the lung.
Results
GC-like structures form in the lung after IAV infection
Following IAV infection, lymphocytic aggregates consisting of T,
B, and dendritic cells form in the lung parenchyma (Fleige et al.,
2014). To determine whether GC B cells exist in these aggregates,
we used Aidcacre-hCD2 mice that express human CD2 as a surro-
gate marker of activation-induced cytidine deaminase (AID), the
canonical GC B cell enzyme. We found clusters of hCD2+ B cells
in close association with CD3+ T cells (Fig. 1 A). These B cells
express both Ki67, a marker of proliferation, and B cell lym-
phoma 6 (Bcl6), a transcriptional regulator required for GC B cell
formation (Vinuesa et al., 2016; Fig. 1 B). The development of
pulmonary GC B cells is slightly delayed compared with those in
the mediastinal LN (medLN; Fig. 1 C). As the output of the lung
GC is not equivalent to that of the medLN (Takahashi et al.,
2017), we sought to characterize the lung GC response further.
Both lung and medLN GC B cells express GL-7 and CD95 (Fig. S1,
A–C), suggesting that lung and LN GC B cells are phenotypically
similar. Lung GC B cells were localized in the parenchyma, as
they did not bind i.v.-administered anti-CD45 (Anderson et al.,
2012; Fig. S1, D and E). To determine whether lung GCs support
plasma cell differentiation, we infected Prdm1GFP/+ mice, in
which GFP marks the expression of B lymphocyte–induced
maturation protein 1 (Blimp1), a transcription factor involved in
terminal differentiation of B cells into plasma cells. After IAV
infection, the lungs of these mice contained a population of GFP+
CD138+ plasmablasts (Fig. S1 F), suggesting that plasma cell de-
velopment accompanies the lung GC response. In SLOs, GC
B cells recirculate between the dark zone (DZ), where they
proliferate and undergo somatic hypermutation, and the light
zone (LZ), where they receive survival and selection signals
from FDCs and Tfh cells (Denton and Linterman, 2017). The
proportion of LZ CXCR4lowCD86hi B cells is increased in the lung
relative to the medLN (Fig. 1, D–F). Confocal microscopy analysis
revealed distinguishable LZ and DZ areas in lung GCs, alongside
rare CD35+ FDCs (Fig. 1 G). Taken together, these data suggest
that while lung GC B cells are phenotypically similar to LN GC,
differences in LZ/DZ partitioning are evident at these two sites,
perhaps due to altered selection efficiency. This prompts the
hypothesis that there may be differences in the provision of
T cell help in lung GCs. However, which T cells provide help in
IAV-induced lung GCs is not known. We identified a population
of CXCR5highPD-1highBcl6+CD4+Foxp3− cells in the IAV-infected
lung that phenotypically resemble Tfh cells (Fig. 1 H), suggesting
that these cells may be the source of T cell help for GC B cells in
the lung.
Tfh cells are required for lung GC formation
To determine if the presence of Tfh-like cells in the lung after
IAV infection is functionally relevant, we tested whether lung
GCs need T cell help to form. Lung GCs were absent in mice that
lack αβ T cells (Tcra−/− mice; Fig. 2 A). The number of Tfh cells
correlates positively with the number of GC B cells in the
medLN (Fig. 2 B) and lung (Fig. 2 C), consistent with interde-
pendence of these two cell types. To formally test the re-
quirement for Tfh-like cells, we infected Tfh cell–deficient
(Bcl6fl/fl Cd4cre/+) animals with IAV and found a complete lack of
GC B cells in the lung (Fig. 2, D–F). In Sh2d1a−/− mice, which
have defective Tfh cell development (Qi et al., 2008), lung GC
formation was also impaired (Fig. 2 G). By contrast, Tbx21fl/fl
Cd4cre/+ mice, which lack Th1 cells (Fig. 2, H and I), have intact
lung Tfh cell and GC B cell responses (Fig. 2, J and K), suggesting
that the provision of help to lung GC B cells comes specifically
from lung Tfh cells.
GC B cells compete with each other for access to T cell–
derived help in the form of receptor-mediated costimulation and
cytokines, such as CD40L and IL-21. B cells that bind antigen and
receive help from Tfh cells acquire expression of c-Myc, pro-
moting their survival and proliferation (Calado et al., 2012;
Dominguez-Sola et al., 2012; Luo et al., 2018). Gain of c-Myc
expression by GC B cells is therefore a functional readout of
competent T cell help. To determine if lung Tfh cells are able to
provide help to lung GC B cells, we infected CmycGFP mice
(Huang et al., 2008) with IAV. We found that the frequency of
c-Myc–expressing GC B cells is lower in the lung than in the
medLN (Fig. 2, L and M), indicating that while positive selection
of GC B cells occurs in the lung, the process is less efficient than
in the draining medLN. We also investigated whether the Tfh-
like T cells in the lung were bona fide Tfh or Tfh precursors by
IL-7Rα staining (Lim and Kim, 2007) and found that the pro-
portion of IL-7Rα+ cells among the CXCR5+PD-1+ Tfh cells was
not different between themedLN and lung (Fig. 2 N). Despite the
subtle differences in T cell–mediated selection and DZ/LZ phe-
notype in lung GC B cells compared with LN GC B cells, the data
obtained thus far indicate that the pulmonary GCs induced by
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Figure 1. GCs are induced in the lung after IAV infection. (A) Confocal image of B220 (green), CD3 (white), and AID (huCD2, blue) staining in lung tissue 14 d
after IAV infection. Scale bar, 50 µm. (B) Flow cytometric plots identifying Bcl6+Ki67+AID+ GC B cells in the draining medLN and lung 14 d after IAV infection.
(C)Quantification of Bcl6+Ki67+AID+ GC B cells (expressed as a percentage of B cells) at indicated time points after IAV infection; symbols show the median, and
error bars show the interquartile range. (A–C) Representative of two independent experiments with four to six mice per group. (D–F) Flow cytometric plots
and quantification of LZ and DZ phenotype Bcl6+Ki67+B220+CD19+ GC B cells in the medLN and lung 14 d after IAV infection. Numbers in D indicate the
proportion of LZ (CXCR4+CD86−) and DZ (CXCR4−CD86+) cells among GC B cells. Representative of two independent experiments with six or seven mice per
group. (G) Confocal image of B220 (white), CD35 (blue), and Ki67 (green) staining in lung tissue 14 d after IAV infection. Scale bar, 200 µm. Representative of
two independent experiments with four mice per group. (H) Flow cytometric plots identifying Bcl6+CXCR5+PD-1+CD4+Foxp3− Tfh cells in the draining medLN
and lung 14 d after IAV infection. Numbers indicate the proportion of Tfh (CXCR5+PD-1+) or non-Tfh (CXCR5−PD-1−) cells among T cells. In bar plots, the height
of the bar is the median, and each symbol represents one biological replicate. Representative of four independent experiments with four to eight mice per
group. Statistical significance was determined with a two-sided Mann–Whitney U test (**, P < 0.01; ***, P < 0.001).
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Figure 2. Tfh cells are required for lung GC formation. (A) Quantification by flow cytometry of lung Bcl6+Ki67+CD19+ GC B cells (expressed as a percentage
of B cells) in Tcra−/− and control C57BL/6 mice 14 d after IAV infection. Representative of two independent experiments with three to eight mice per group. (B
and C) Correlation of Bcl6+Ki67+CD19+ GC B cells and Bcl6+PD-1+CD4+Foxp3− Tfh cells in the medLN (B; R2 = 0.82, P < 0.0001) and lung (C; R2 = 0.75, P <
0.0001) 14 d after IAV infection. R2 and P values were calculated using Pearson correlation coefficient. Data are representative of three independent ex-
periments with 15–16 mice per group. (D–F) Flow cytometric dot plots (D) and quantification of CXCR5+PD-1+CD4+Foxp3− Tfh cells (E) and Bcl6+Ki67+CD19+
GC B cells (F) in the lung 14 d after IAV infection of Bcl6fl/flCd4cre/+ mice and Bcl6fl/flCd4+/+ littermate controls. Numbers in D indicate the proportion of
CXCR5+PD-1+ Tfh cells among T cells. Data are representative of three independent experiments with six to eight mice per group. (G) Quantification of
Bcl6+Ki67+CD19+ GC B cells in the lung 14 d after IAV infection of Sh2d1a−/y mice and Sh2d1a+/y littermate controls. Data are representative of two independent
experiments with six mice per group. (H–J) Flow cytometric contour plots (H) and quantification of CXCR3+Tbet+CD4+Foxp3− Th1 cells (I), CXCR5+PD-
1+CD4+Foxp3− Tfh cells (J), and Bcl6+Ki67+CD19+ GC B cells (K) in the lung 14 d after IAV infection of Tbx21fl/fl Cd4cre/+ mice and Tbx21fl/fl Cd4+/+ littermate
controls. Numbers in H indicate the proportion of CXCR3+T-bet+ cells among T cells. Data are representative of three independent experiments with six to eight
mice per group. (L andM) Flow cytometric dot plots (L) and quantification of the proportion of GL-7+CD38−B220+CD19+ GC B cells (M) expressing c-Myc (GFP)
in the medLN and lung 14 d after IAV infection. Numbers in L indicate the proportion of GFP+ (c-Myc+) cells among GC B cells. Data are representative of three
independent experiments with four to eight mice per group. (N) Proportion of IL-7Rα+ cells among CXCR5+PD-1+CD4+ Tfh cells in the medLN and lung 14 d
after IAV infection. Data are representative of two independent experiments with six or seven mice per group. In bar plots, the height of the bar is the median,
and each symbol represents one biological replicate. Statistical significance was determined with a two-sided Mann–Whitney U test (*, P < 0.05; **, P < 0.01;
***, P < 0.001; ****, P < 0.0001).
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viral infection are largely similar to those observed in the LN,
albeit with a distinct antibody output (Adachi et al., 2015).
Within SLOs, GC structure is largely driven by oxysterol and
chemokine-derived signals that coordinate B and T cell locali-
zation and movement, and these ligands are produced by spe-
cialized mesenchymal stromal cell types within the SLO, such as
FDCs (Wang et al., 2011; Denton et al., 2014; Denton and
Linterman, 2017). Because the lungs do not have this special-
ized stromal cell network, IAV infectionmust induce remodeling
of lung tissue first to recruit, and then to organize, lymphocytes
into functional GC-like structures.
CXCR5–CXCL13 signaling drives B cell recruitment to the lung
after infection
The first step required for the initiation of a GC is the re-
cruitment of antigen-specific T and B cells. To understand how
this is controlled in the lung after IAV infection, we monitored
recruitment of CD4+ T cells and B cells to the lung parenchyma
by labeling vascular hematopoietic cells with i.v.-injected anti-
CD45 (Fig. S1, D and E). In the absence of infection, the majority
of T and B cells in the lung are in the blood vessels; after in-
fection, cells are recruited into the parenchyma with infiltra-
tion, peaking 6 d after infection for B cells and 9 d after
infection for CD4+ T cells (Fig. 3, A and B). To determine what
signals control B cell recruitment to the lung, we first consid-
ered the role of CXCR3, which is expressed by some B cell
subsets after activation (www.immgen.org) and by iBALT
B cells in chronic obstructive pulmonary disease (COPD) pa-
tients (Kelsen et al., 2009). Furthermore, the CXCR3 ligands
CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-TAC) are induced
by IAV infection (Groom and Luster, 2011). However, Cxcr3fl/fl
Tg(Fcer2acre) animals that lack CXCR3 specifically on mature
B cells (Fig. S2 A) do not have impaired B cell migration to the
lung following IAV infection (Fig. 3 C). This led us to speculate
that naive B cells may be directly recruited to the lung and
activated locally. To test this hypothesis, we assessed whether
B cells specific for an antigen irrelevant to IAV, hen egg lyso-
zyme (HEL), can be recruited to the lung after IAV infection.
We infected SWHEL mice (Phan et al., 2003), in which 10–30%
of B cells have a B cell receptor specific for HEL, with IAV and
found that HEL-binding B cells entered the lung parenchyma at
the same frequency as polyclonal B cells (Fig. 3 D). This dem-
onstrates that B cells do not require antigen-mediated activa-
tion before entry into the lung, suggesting that recruitment to
the lung may be independent of activation in the LN. To de-
termine whether B cells are activated in the LN before entry to
the lung, we lethally irradiated Rag2−/−Il2rg−/− mice and re-
constituted them with WT bone marrow (BM) to generate mice
with a full complement of immune cells but lacking LNs. In
these mice, B cells are not compromised in their ability to enter
the lung parenchyma 5 d after IAV infection. Rather, an in-
creased proportion of B cells could enter the lung in the absence
of LNs (Fig. 3 E). In support of this notion, prevention of
lymphocyte egress from SLOs by treatment with the S1P re-
ceptor agonist FTY720 reduces the number of B cells in the lung
vasculature, but not in the lung parenchyma (Fig. 3, F and G).
Taken together, these data demonstrate that B cell recruitment
to the lung following IAV infection is independent of LN traf-
ficking and B cell receptor signaling.
The entry of naive B cells into SLOs is antigen independent
and driven by the chemokines C-C motif ligand 19 (CCL19),
CCL21, CXCL12, and CXCL13, which are produced by the stromal
cell network within the lymphoid tissues (Fo¨rster et al., 1999;
Okada et al., 2002; Denton and Linterman, 2017). While these
chemokines are constitutively expressed in SLOs, they are not
abundantly expressed in the naive lung. Rather, chemokines
such as CXCL13 and CCL21 are induced in the lung after IAV
infection (Moyron-Quiroz et al., 2004).We hypothesized that, in
order to recruit naive B cells to initiate a GC in the lung, IAV
infection induces expression of these chemokines in local me-
senchymal cells. We confirmed that Cxcl13 and Ccl19 are induced
in the lung following IAV infection, with expression of mRNA
peaking 5–6 d after infection (Fig. 3 H), before formation of GC-
like iBALT structures. To determine if B cell entry in the lung is
driven by responsiveness to C-C motif receptor 7 (CCR7) ligands
(CCL19 and CCL21), we generated BM chimeras in which all
B cells lacked CCR7 expression (B:Ccr7−/−). Following IAV in-
fection, B cell trafficking into the lung parenchyma (CD45i.v.-
negative B cells) was equivalent between control chimeras and
those in which B cells lack CCR7 expression (Fig. 3 I), demon-
strating that CCR7 is not necessary for B cell trafficking to the
lung. Finally, we excluded a role for Tfh cells in directing B cell
trafficking into the lung following IAV infection, as
Cd4cre/+Bcl6fl/fl animals, which lack Tfh cells, showed no change
in the proportion of B cells that had entered the lung paren-
chyma or the induction of Cxcl13 mRNA 6 d after IAV infection
(Fig. S2, B and C).
To determine whether B cell entry to the lung requires
CXCR5-dependent migration toward infection-induced CXCL13,
we generated mice in which mature B cells specifically lack
CXCR5, namely Cxcr5fl/fl Tg(Fcer2acre) mice. 6 d after IAV in-
fection, B cell recruitment into the lung is impaired in thesemice
(Fig. 3 J). Because the frequency of B cells in the lung paren-
chyma of uninfected Cxcr5fl/fl Tg(Fcer2acre)mice is similar to that
of control animals (Fig. 3 K), these data demonstrate that during
infection with IAV, CXCR5 is required by B cells for their mi-
gration into the lung.
To determine the impact of impaired B cell recruitment on
the formation of lung GCs, we assessed B cell responses in
Cxcr5fl/fl Tg(Fcer2acre) mice 14 d after IAV infection. Consistent
with the day 6 data (Fig. 3 I), the frequency of B cells in the lung
parenchyma was reduced in Cxcr5fl/fl Tg(Fcer2acre) mice com-
pared with controls (Fig. 4, A and B), as was the proportion of GC
B cells (Fig. 4 C), demonstrating that CXCR5 is important for the
GC B cell response in the lung. Because CXCR5 contributes to
B cell migration in SLOs (Fo¨rster et al., 1996), we also inhibited
CXCL13 in WT mice to exclude any potential artifacts due to
altered development and/or homeostasis of CXCR5-deficient
B cells. We administered a CXCL13 blocking antibody
(Klimatcheva et al., 2015) on days 0, 3, 7, and 10 after IAV in-
fection (Fig. 4 D). This treatment left GC responses intact in the
draining medLN 14 d after IAV infection (Fig. 4 E), but both
B cell recruitment to and GC formation within the lung were
reduced in anti-CXCL13–treated mice (Fig. 4, F and G). While
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Figure 3. De novo induction of Cxcl13 recruits B cells into the lung after IAV infection. (A) Proportion of CD4+ T cells and B220+ B cells in the lung
parenchyma at the indicated days after IAV infection. Parenchymal lymphocytes are defined as those that do not bind anti-CD45 administered i.v. 3 min before
euthanasia. (B) Confocal images of CD31+ blood vessels (red), CD3+ T cells (white), and B220+ B cells (blue) at indicated days after IAV infection. Scale bar,
100 µm. (A and B) Data are representative of two independent experiments with five mice per group. (C) Flow cytometric histogram and quantification of
CD45i.v.−B220+CD19+ B cells in the lung 6 d after IAV infection of Cxcr3fl/fl Tg(Fcer2acre)mice and Cxcr3+/+ Tg(Fcer2acre) control mice. Data are representative of
two independent experiments with four or five mice per group. (D) Representative flow cytometric dot plot, and proportions of polyclonal or HEL-binding
B220+CD19+ B cells that are CD45i.v.− in the lung 6 d after IAV infection of SWHEL mice. Numbers indicate the proportion of cells within each quadrant among
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the total GC B cell frequency was not altered in the medLN
following anti-CXCL13 treatment (Fig. 4 E), the medLN GC
structure exhibited subtle changes (Fig. 4 H). The GC was
slightly larger in area (Fig. 4 I), in most part due to expansion of
the DZ (Fig. 4 J) in anti-CXCL13–treated mice. Thus, B cell
trafficking to the lung and subsequent GC formation at this site
occur independently of GC responses in the draining LN but
require CXCR5–CXCL13 signaling.
These results also raise the question of whether CXCR5 is
required solely for B cell migration to the lung or whether
CXCR5–CXCL13 signaling has a direct role in GC organization
within the lung. To test whether CXCL13 is required for lung GC
maintenance, we administered a CXCL13-blocking antibody on
days 14 and 17 relative to IAV infection (Fig. 4 K). 20 d after
infection, B cell recruitment to the lung is unaffected (Fig. 4 L),
as is the frequency of lung GC B cells (Fig. 4 M). Consistent with
this observation, GC B cell frequency in the lung of Cxcr5fl/fl
Tg(Fcer2acre) mice is equivalent to controls when assessed as a
proportion of those B cells that have entered the lung paren-
chyma (Fig. 4 N). Taken together, these data demonstrate that
CXCL13 promotes the recruitment of B cells to the lung but is
dispensable for lung GC maintenance once B cells have entered
the lung parenchyma.
IAV infection induces CXCL13 expression in
pulmonary fibroblasts
To understand how CXCL13 is induced in the lung after IAV
infection, we sought to identify the pulmonary cell type inwhich
it is expressed. 5 d after infection, Cxcl13 mRNA is increased in
lung platelet-derived growth factor receptor α (PDGFRα)+ fi-
broblasts, but not hematopoietic cells, epithelial cells, or endo-
thelial cells, relative to uninfected controls (Fig. 5 A; the gating
strategy is shown in Fig. S3). We also observed that B cell
clusters were typically localized around CXCL13-expressing
stromal cells in IAV-infected Tg(Cxcl13cre-dTomato) mice (Onder
et al., 2017; Fig. 5 B). Flow cytometry analysis confirmed that
the CXCL13-expressing cells are PDGRFα+ fibroblasts that also
express podoplanin (gp38), a signature molecule of immuno-
modulatory fibroblasts within SLOs (Acton et al., 2014; Fig. 5, C
and D).
To determine whether CXCL13-expressing pulmonary fi-
broblasts were phenotypically distinct from those not ex-
pressing CXCL13, we characterized the expression of six
common stromal cell markers (gp38, PDGFRα, CD21/35, MHC
II, Sca1, and CD44) on CD45−CD31−PDGFRα+CXCL13+ and
CD45−CD31−PDGFRα+CXCL13− cells isolated from lungs of mice
infected with IAV 5 or 14 d earlier. CD21/35 is the canonical
marker for LN FDCs; Sca1 and CD44 can be used to define
mesenchymal stem/stromal cells, although their exact func-
tions are yet to be determined. While the expression of PDGFRα
was not different between the two populations, pulmonary
CXCL13+ fibroblasts expressed slightly but significantly higher
levels of gp38 and Sca1 relative to CXCL13− fibroblasts both 5
and 14 d after IAV infection (Fig. 5 E). Strikingly, 99% of CXCL13+
fibroblasts did not express the FDC marker CD21/35, indicat-
ing that they are not FDC-like (Fig. 5 F), even though CD35+
FDC-like cells can be found in IAV-induced pulmonary GCs
(Fig. 1 H). CXCL13+ fibroblasts also had lower levels of MHC II
and greater levels of CD44 relative to CXCL13− fibroblasts both
5 and 14 d after IAV infection (Fig. 5 F). Taken together, these
data demonstrate that pulmonary CXCL13+ fibroblasts are
not FDC-like and are phenotypically distinct from total lung
fibroblasts.
Since CXCL13-expressing fibroblasts are barely detectable in
uninfected mice, CXCL13 expression must be induced de novo
in the lung after IAV infection. Induction of Cxcl13 mRNA is
independent of T, B, or innate lymphoid cells, as Rag2−/−Il2rg−/−
and control mice have similar expression of Cxcl13 mRNA fol-
lowing IAV infection (Fig. 6 A), suggesting an early inflam-
matory mediator may be involved. To implicate a soluble
mediator in Cxcl13 induction, we next assessed the expression
kinetics of cytokine mRNAs that are induced after IAV infec-
tion in a whole-lung transcriptome dataset where samples had
been assessed over a time course of infection (Oslund and
Baumgarth, 2011; Pommerenke et al., 2012). The induction of
mRNAs encoding IL-6 and IFNβ preceded Cxcl13 expression
(Fig. 6 B), while genes encoding IL-1β, type III IFNs, granulocyte
colony-stimulating factor, TNF, and IFNγ were all induced
early after IAV infection, albeit with a similar expression pat-
tern to Cxcl13 (Fig. 6 B). This expression pattern indicated that
these cytokines may be causal in inducing Cxcl13 in lung fi-
broblasts after IAV infection. In vitro, IFNα and IFNβ were the
only cytokines that were consistently able to induce Cxcl13
transcripts in lung fibroblasts (Fig. 6 C), suggesting they may be
important factors that promote pulmonary Cxcl13 expression
in vivo.
B220+CD19+ B cells. Data are representative of two independent experiments with four mice per group. (E) Proportion of parenchymal B cells, as determined
by lack of CD45i.v. labeling, in either WT or Rag2−/−Il2rg−/− mice that have been irradiated and reconstituted with WT BM 8 wk before infection. Data are
representative of two independent experiments with 8–10 mice per group. (F and G) Number of B cells in the blood (F; CD45i.v.+B220+CD19+CXCR5+) or the
lung parenchyma (G; CD45i.v.−B220+CD19+CXCR5+) 6 d after IAV infection, where FTY720 was administered on days 3 and 5 after IAV infection. Data are
representative of two independent experiments with five mice per group. (H) Quantitative RT-PCR detection of Cxcl13 and Ccl19 transcripts in whole-lung
mRNA at the indicated days after IAV infection. Data are representative of two independent experiments with three mice per group. (I) Quantification of
CD45i.v.−B220+CD19+ B cells in the lung parenchyma 6 d after IAV infection of B:Ccr7−/− chimeras and control B:Ccr7+/+ chimeras. Data are representative of
two independent experiments with six to eight mice per group. (J)Quantification of CD45i.v.−B220+CD19+ B cells in the lung parenchyma 6 d after IAV infection
of Cxcr5fl/fl Tg(Fcer2acre) mice and Cxcr5+/+ Tg(Fcer2acre) control mice. Data are representative of five independent experiments with four to seven mice per
group. (K) Quantification of CD45i.v.−B220+CD19+ B cells in the lung parenchyma in uninfected Cxcr5fl/fl Tg(Fcer2acre) mice and Cxcr5+/+ Tg(Fcer2acre) control
mice. Data are representative of two independent experiments with five mice per group. In A and H, each symbol represents the median; the error bars show
standard deviation. In bar plots, the height of the bar is the median, and each symbol represents one biological replicate. In C and E–K, statistical significance
was determined with a two-sided Mann-Whitney U test. In D, the P value was calculated using a paired t test and is representative of two independent
experiments. **, P < 0.01.
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Figure 4. B cell–intrinsic CXCR5 expression is required to establish a lung GC response but is dispensable for its maintenance. (A) Flow cytometric
histogram of CXCR5 expression on lung CD19+B220+ B cells from Cxcr5fl/fl Tg(Fcer2acre)mice and Cxcr5+/+ Tg(Fcer2acre) control mice 14 d after IAV infection. (B
and C) Quantification of CD45i.v.−B220+ (B) and Ki67+Bcl6+B220+ GC B cells (C) in the lung parenchyma 14 d after IAV infection of Cxcr5fl/fl Tg(Fcer2acre) mice
and Cxcr5+/+ Tg(Fcer2acre) control mice. Data are representative of four independent experiments with five to eight mice per group. (D) Experimental design of
experiment to block CXCL13 through IAV infection. (E–G) Proportion of medLN Ki67+Bcl6+B220+ GC B cells (E) and CD45i.v.−B220+ B cells (F) in the lung
parenchyma and lung Ki67+Bcl6+B220+ GC B cells (G) in WTmice dosed with anti-CXCL13 antibody or isotype control as shown in D. Data are representative of
two independent experiments with 10 mice per group. (H) Confocal image of medLNs frommice treated as in D showing the GC as defined by CD3 (white), IgD
(red), CD35 (blue), and Ki67 (green) staining. Scale bar, 200 µm. (I and J) Analysis of medLN GC structure after anti-CXCL13 administration, quantifying GC size
(in square micrometers; I) and the proportion of the GC that is DZ, as defined by Ki67 positivity (J). Data are representative of two independent experiments
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Type I IFN induces Cxcl13 expression in vivo
Type I IFNs are produced by virally infected cells to limit viral
spread (Sanders et al., 2011). Ifnb1 mRNA was induced in CD45+
cells and epithelial cells 5 d after IAV infection (Fig. 6 D), in line
with the cell types previously shown to be directly infected by
IAV (Sanders et al., 2011). To determine if the type I IFN pro-
duced by these cells supports Cxcl13 induction in the lung during
IAV infection, we analyzed whole-lung microarray data from
IAV-infected animals that lack the IFNα/β receptor 1 (IFNAR1)
and therefore type I IFN signaling (Cilloniz et al., 2010). We
examined genes that changed differently over time in control
and Ifnar1−/− animals and confirmed that the induction of type I
IFN responsive genes was impaired in Ifnar1−/− mice (Fig. 6 E,
top). We then assessed how global chemokine expression was
altered using the same unbiased approach. Six chemokines were
significantly reduced in the lungs of mice that lacked IFNAR1,
with Cxcl13 being the most affected (Fig. 6 E, bottom). Cxcl13
mRNA was significantly reduced (by 50%) in the lungs of
Ifnar1−/−mice 3 d after IAV infection (Fig. 6 F). Although Ifnar1−/−
mice have reduced expression of Cxcl13 3 d after IAV infection,
these mice were able to recruit B cells to the lung and form
pulmonary GCs 14 d after infection (Fig. S4, A and B). This was
also observed in mice lacking IFNAR1 in nonhematopoietic cells
(Fig. S4, C and D). Ifnar1−/− mice had enhanced production of
inflammatory mediators such as Il1a (Fig. S4 E), likely caused by
excessive viral replication in these mice (Fig. S4 F; Seo et al.,
2011). IL-1 has been shown to support iBALT formation in vivo
(Kuroda et al., 2016; Neyt et al., 2016), suggesting that redundant
mechanisms are in place to ensure iBALT formation during IAV
infection.
Combinatorial treatment with IFNβ and cGAMP induces B cell
trafficking and pulmonary GC formation in the absence of
viral infection
To determine if type I IFN is sufficient to induce Cxcl13 expres-
sion in the lung in vivo, in the absence of viral infection, we
administered a single dose of IFNβ i.n. The canonical IFN-
inducible gene Mx1 was induced 24 h after treatment
(Fig. 6 G). This single dose of type I IFN was also able to induce
Cxcl13 mRNA in the lung at the same time point (Fig. 6 H),
demonstrating that this cytokine can induce pulmonary Cxcl13
expression. We next sought to determine whether it could also
induce B cell trafficking. We administered three doses of IFNβ
i.n. at intervals of 2 d (Fig. 7 A) andmeasured B cell responses on
day 6. We found that IFNβ alone did not induce significant B cell
trafficking into the lung (Fig. 7 B), despite CXCL13 being the key
chemokine for B cell recruitment during IAV infection (Fig. 4).
We hypothesized that this may be because B cells require a
second signal, in addition to chemokines, to be retained in the
lung after recruitment. As B cells can be recruited to the lung
parenchyma without BCR triggering (Fig. 3 D) a second signal
was likely to be delivered by a pathogen- or danger-associated
signal. To test this, we coadministered IFNβ with 2939-cyclic
GMP-AMP (cGAMP), a nucleoside analogue that can potentiate
B cell activation via the STING pathway (Walker et al., 2018),
using the same experimental protocol as in Fig. 7 A. While IFNβ
or cGAMP alone could not induce B cell trafficking, the combi-
nation of these molecules induced significant influx of B cells
into the lung parenchyma (Fig. 7 C). We then determined
whether this combination therapy was sufficient to induce
pulmonary GCs. To this end, we administered the model im-
munogen NP-KLH with or without IFNβ and/or cGAMP for 3 d
and determined the development of medLN and pulmonary GCs
14 d after the first dose. The combination of IFNβ and cGAMP
induced strong GC responses in both the medLN and the lung,
including the development of antigen-specific NP+IgG1+ GC
B cells (Fig. 7 D). We found striking differences in the capacity of
these stimulants to induce pulmonary and medLN GCs: while
IFNβ, cGAMP, and the combination could induce some medLN
GC formation, only the combination of IFNβ and cGAMP was
able to induce pulmonary GC formation, in line with the re-
quirement for both of these molecules to induce B cell trafficking
to this tissue. These data demonstrate that the requirements for
SLO and ectopic GC formation are distinct, perhaps explaining
the differences in GC output from these two sites (Adachi et al.,
2015).
Discussion
In the humoral response to IAV, the induction of broadly neu-
tralizing cross-reactive antibodies has excellent therapeutic
potential, as this may provide protection against multiple IAV
strains. How the immune system balances the generation of
highly specific and cross-reactive antibodies is, however, poorly
understood. The formation of pulmonary GCs following IAV
infection is sufficient to protect against subsequent infection
(Moyron-Quiroz et al., 2004), demonstrating the potency of this
local immune response. Mice that lack SLOs also survive higher
doses of IAV infection, suggesting that the inflammation induced
in the lung alone is less pathogenic than the systemic immune
response (Moyron-Quiroz et al., 2004, 2006). Differences in
output from SLOGCs compared with pulmonary GCs during IAV
infection (Adachi et al., 2015) suggest that anatomical location
may impact on GC quality. Here, we have shown that type I IFN,
produced by infected epithelial cells to combat viral spread
(Sanders et al., 2011), also coordinates the local adaptive immune
response in the lung. CXCL13 expression is induced in lung fi-
broblasts by type I IFN signaling and this in turn facilitates the
with five mice per group. (K) Experimental design of the experiment to block CXCL13 after GC formation. (L andM) Proportion of CD45i.v.−B220+ B cells in the
lung parenchyma (L) and lung Ki67+Bcl6+B220+ GC B cells (M) in C57BL/6 mice dosed with anti-CXCL13 antibody or isotype control as shown in H. Data are
representative of two independent experiments with 10 mice per group. (N) Frequency of Ki67+Bcl6+B220+ GC B cells within the CD45i.v.− lung resident B cell
population in Cxcr5fl/fl Tg(Fcer2acre) mice and Cxcr5+/+ Tg(Fcer2acre) control mice 14 d after IAV infection. Data are representative of four independent ex-
periments with five to eight mice per group. In bar plots, the height of the bar is the median, and each symbol represents one biological replicate. In I and J, box
and whiskers show the 10th–90th percentile range. P values shown were calculated using a Mann–Whitney U test (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
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Figure 5. IAV infection induces CXCL13 in pulmonary PDGFRα+ fibroblasts. (A) Quantitative RT-PCR analysis of Cxcl13 in the indicated cell populations
purified from the uninfected lung or lung 5 d after IAV infection. Data are representative of two independent experiments with three mice per group. (B–D)
Confocal images (B) of CXCL13-tdTomato (red), CD31 (white), and B220 (blue) and flow cytometry quantification (C and D) of CXCL13-expressing cells in lung
tissue 5 d after IAV infection of Tg(Cxcl13cre-dTomato) or littermate control mice. Scale bar, 100 µm. Numbers in C indicate the proportion of RFP+ cells within the
indicated populations. Data are representative of three independent experiments with four to eight mice per group. (E and F) Flow cytometric phenotyping of
CD45−CD31−PDGFRα+CXCL13+ (gray) and CXCL13− (white) cells isolated 5 and 14 d after IAV infection from lung alongside CD45+ cells for staining reference (F
only, dashed line). The expression of gp38, PDGFRα, or Sca1 (E) and CD21/35, MHC II, or CD44 (F) in the indicated populations was determined by mean
fluorescence intensity (MFI) of staining or proportion of cells expressing the marker (CD21/35 only). Data are representative of three independent experiments
with four to six mice per group. P values in A and D were calculated using a two-way ANOVA. P values in E and F were calculated using a Mann–Whitney U test.
*, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 6. Type I IFN induces Cxcl13 expression in the lung in vivo. (A) Cxcl13 induction in whole-lung mRNA in Rag2−/−Il2rg−/− and Rag2+/+Il2rg+/+ WT
control mice 5 d after IAV infection. Data are representative of two independent experiments with five or six mice per group. (B) Heat map of cytokine mRNA
expression from a whole-lung microarray dataset at the indicated days after IAV infection. Expression for each probeset is shown relative to mock-infected
animals. Data were reanalyzed from a previously published dataset (Pommerenke et al., 2012). (C) Quantitative RT-PCR analysis of Cxcl13 in lung fibroblasts
stimulated with the indicated cytokine for 6 h in vitro, the dotted line indicates a fold change of one over unstimulated cells. In all dot plots, each symbol
represents an independent biological replicate, and data are representative of three independent experiments with four mice per group. (D) Quantitative RT-
PCR analysis of Ifnb1 in the indicated cell populations purified from the uninfected lung, or lung 5 d after IAV infection. Ifnb1 level is represented as expression
relative to Gapdh in each cell type; nd, not detected. Data are representative of two independent experiments with three mice per group. (E) Regression
coefficients for each gene are plotted against mean normalized gene expression values (change from day 1 to day 3; WT vs. Ifnar1−/−). IFN-responsive (top) or
chemokine (bottom) genes are highlighted in blue (P > 0.05) or red (P < 0.05; F test across days 1, 3, and 4, after multiple correction testing). (F) Expression of
pulmonary Cxcl13 relative to uninfected animals 3 d after IAV infection as determined by microarray. Data were reanalyzed from a previously published dataset
(Cilloniz et al., 2010). (G and H) Quantitative RT-PCR for Mx1 (G) and Cxcl13 (H) in whole-lung mRNA samples taken 24 h following i.n. administration of IFNβ.
Data are representative of two independent experiments with ten mice per group. For two-way comparisons, P values shown were calculated using a
Mann–Whitney U test. **, P < 0.01; ***, P < 0.001. In all dot plots, each symbol represents an independent biological replicate.
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CXCR5-dependent recruitment of B cells to the lung to initiate a
GC response. Moreover, administration of type I IFN in con-
junction with a second signal drives recruitment of B cells into
the lung parenchyma and is sufficient for the formation of
functional pulmonary GCs. The formation of functional GCs in
the lung, in parallel with those in SLOs, at first glance appears to
be an energetically expensive duplication of effort. However,
analysis of the lung B cell repertoire after IAV infection reveals
different antibody repertoire usage at this site compared with
the LN, one that would generate more broadly neutralizing an-
tibodies (Adachi et al., 2015; Takahashi et al., 2017). Together,
this suggests that compounds that stimulate a type I IFN re-
sponse may be useful as vaccine adjuvants to generate cross-
protective B cell responses at mucosal sites.
While it is clear that GC responses in TLSs are qualitatively
different from those in SLOs, how this difference in B cell re-
ceptor repertoire is generated is not clear. Here, we show that
c-Myc is induced in fewer lung GC B cells thanmedLNGC B cells,
indicating alterations in positive selection in the lung. This
might be due to impaired access to antigen, reduced specific
antigen display among a broader range of antigens, or reduced
T cell help. This may also be the cause of the increased pro-
portion of LZ phenotype GC B cells in the lung, as fewer cells
may receive cues that would prompt them to acquire a DZ
phenotype. Impaired selection of GC B cells in the lung may
occur because the structure of ectopic GC is not as organized as
that of the GC in SLOs (Moyron-Quiroz et al., 2004, 2006;
Denton and Linterman, 2017), making access to Tfh cells and/or
immune complexes less likely. Limitations of either or both
signals would alter the selection of B cells that emerge from the
GC as long-lived plasma cells or memory B cells, thereby altering
the repertoire of effector B cells produced in the lung.
Our results indicate that the IAV infection–induced remod-
eling of lung fibroblasts makes them functionally resemble the
CXCL13-producing FDCs in the B cell follicle of SLOs. It is clear
from our data that pulmonary CXCL13+ fibroblasts are not FDCs,
despite the detection of rare CD35+ FDC-like cells in pulmonary
GCs, and are phenotypically distinct from pulmonary CXCL13−
fibroblasts; lung CXCL13+ fibroblasts do not express the canon-
ical FDC marker CD21/35 and have differential cell-surface
expression of gp38, MHC II, Sca1, and CD44. CXCL13-expressing
cells that do not express CD35 have been observed in pulmonary
adenocarcinoma–associated TLSs (Joshi et al., 2015) and in the
omentum (Rangel-Moreno et al., 2009). These data suggest that
the pathway that induces CXCL13 expression in inflammatory
conditions is distinct from that which supports LN FDCs. Indeed,
signaling through the lymphotoxin-β receptor (LTβR) is critical to
the formation and maintenance of the LN FDC network that
supports the B cell follicle and GC formation, as these structures
are unstable in mice with disrupted LTβR signaling (Brendolan
and Caamaño, 2012) and poorly organized in mice that lack the
LTβR on LN mesenchymal stromal cells (Onder et al., 2017). By
Figure 7. IFNβ combined with cGAMP induces B cell
trafficking and pulmonary GCs. (A and B) WT mice were
administered IFNβ i.n. on days 0, 2, and 4 (A), and the ability
of B cells to enter the lung parenchyma was determined on
day 6 by i.v. anti-CD45 labeling (B). Data are representative
of four independent experiments with five mice per group.
(C)WTmice were treated with IFNβ and/or cGAMP i.n. as in
A, and the proportion of B cells that had entered the lung
parenchyma was determined by anti-CD45i.v. labeling. Data
are representative of two independent experiments with
five mice per group. (D–F)WT mice were administered NP-
KLH with IFNβ and/or cGAMP i.n. on days 0, 1, and 2, and
the development of GCs was determined in the lung and
medLN 14 d after the first dose. GC B cell staining (D) in
medLN (top) and lung (bottom) is shown for mice admin-
istered NP-KLH/IFNβ/cGAMP, determined by Bcl6 and Ki67
expression on B220+CD19+CD45+ cells. Antigen specificity
was also demonstrated by costaining for NP and IgG1 on GC
B cells (CD45+CD19+B220+Bcl6+Ki67+). Numbers in flow
plots (D) indicate the proportion of GC B cells among B cells
and the proportion of GC B cells that are antigen specific.
The proportion of GC B cells was also determined in the
medLN (E) and lung (F) in all treatment groups. Data are
representative of two independent experiments with five
mice per group. P values were calculated using a two-way
ANOVA test, and each symbol represents a biological rep-
licate. **, P < 0.01; ***, P < 0.001; ns, not significant.
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contrast, induction of CXCL13 in the lung after IAV infection oc-
curs independently of lymphotoxin signaling (Moyron-Quiroz
et al., 2004) and LTi cells (Rangel-Moreno et al., 2011), demon-
strating that there are distinct pathways responsible for initiating
de novo CXCL13 expression in adulthood. The induction of CXCL13
by type I IFN, reported here, is one such mechanism.
Type I IFN is not the only cytokine able to induce CXCL13 in
nonlymphoid tissues. In response to particulate antigens and
viral infection, CXCL13 can be induced in lung fibroblasts via IL-
1 signaling (Kuroda et al., 2016; Neyt et al., 2016), by IL-22 in the
salivary gland in a mouse model of Sjo¨gren’s syndrome (Barone
et al., 2015), or in the fat by TNF (Be´ne´zech et al., 2015). Fur-
thermore, treatment of neonates with LPS results in CXCL13
induction and iBALT formation in an IL-17-dependent fashion
(Rangel-Moreno et al., 2011). Together, these studies highlight
the fact that multiple pathways have the potential to induce
pulmonary CXCL13 expression. Such redundancy in biological
systems is common and may have evolved to ensure that TLSs
are able to form in response to a number of infections that may
induce a different inflammatory environment.
While this study focused on the generation of pulmonary GCs
during IAV infection, ectopic GCs have been described in a
number of inflammatory disorders, includingmultiple antibody-
mediated autoimmune disorders (Psarras et al., 2017), cancer,
and COPD. In COPD patients, there is a positive correlation be-
tween CXCL13 expression and B cell accumulation in the lung
(Hogg et al., 2004), suggesting that a CXCL13-dependent
mechanism of B cell recruitment occurs in human disease.
While the link between type I IFN and TLS formation is difficult
to test in humans, there are a number of autoimmune diseases
that have been described as having an “IFN signature,” in which
excessive type I IFN activity is a key feature of disease. These
include systemic lupus erythematosus, insulin-dependent dia-
betes mellitus, rheumatoid arthritis, Sjo¨gren’s syndrome, der-
matomyositis, systemic sclerosis (Ro¨nnblom and Eloranta,
2013), and the rare, lupus-like monogenic interferonopathies
(Rodero and Crow, 2016). Whether the IFN in these conditions is
pathogenic or a consequence of disease remains unresolved,
although IFN blockade trials are ongoing (Psarras et al., 2017).
The majority of diseases with an IFN signature do, however,
have autoantibodies and GC-containing ectopic lymphoid tissue
within the target tissues (Pitzalis et al., 2014). This, together
with the work presented here, suggests that type I IFN may
trigger the formation of GC-containing TLSs in autoimmune
disease. Perturbation of this axis, either by IFN or CXCL13
blockade, has promise in the treatment of a panoply of auto-
immune and inflammatory diseases, while stimulation of this
system via intranasal vaccination may promote protective
immunity.
Materials and methods
Mice, infections, treatments, and in vivo labeling
Mice on the C57BL/6 background used in this study were de-
rivatives of the following: Tcra−/−, Cd4cre, Cxcr5fl/fl (Bradford
et al., 2017), Bcl6fl/fl, Aicdacre-hCD2, Tbx21fl/fl, Tg(Fcer2acre),
CmycGFP, Rag2−/−, Tg(Cxcl13cre-dTomato), Prdm1GFP/+, and SWHEL
mice. Cxcr3fl/fl conditionally deleted mice were generated as
described previously (Piovesan et al., 2017). All mice were be-
tween 8 and 14 wk of age at the start of the experiment, and both
male and female mice were used. No significant differences
were observed between the sexes. For experiments using cre-
driven transgenic animals, control mice were age- and sex-
matched cousins unless otherwise indicated. Mice were bred
and maintained in specific-pathogen–free conditions in the Bi-
ological Services Unit, Babraham Research Campus. All proce-
dures performed in the UK were approved by the Animal
Welfare and Ethical Review Body of the Babraham Research
Campus and the UK Home Office. Experiments using Cxcr3fl/fl
Tg(Fcer2acre) mice and controls were performed at the Walter
and Eliza Hall Institute. These animal procedures were approved
by both WEHI and Monash University Animal Ethics Commit-
tees. Mice were administered 104 plaque-forming units of in-
fluenza A/Hong Kong/1/1968/x31 (x31) virus, 4 × 105 IU
Betaferon (IFNβ; Bayer), 100 µg NP-KLH (BioSearch Technolo-
gies), and/or or 2 µg cGAMP (SML1229; Sigma) i.n. under in-
halation anesthesia. Circulating hematopoietic cells were labeled
in vivo by i.v. administration of 3 µg biotinylated- or APC-
conjugated CD45 (30-F11; BioLegend) antibody 3 min before
euthanasia, followed by ex vivo detection with fluorochrome-
conjugated streptavidin where appropriate. For antibody
blocking experiments, mice were administered 56 mg/kg anti-
CXCL13 or isotype control antibody (Vaccinex) i.p. as indicated
in the text. For inhibition of LN egress, mice were administered
200 µg FTY720 (Cayman) i.p. 3 and 5 d after IAV infection. For
preparation of BM chimeras, Rag2−/− recipient mice were sub-
lethally irradiated with 750 rad and reconstituted via i.v. injec-
tion with 2 × 106 donor BM cells. Chimeric mice were infected
with IAV 8 wk after irradiation and cell transfer. For BM chi-
meras in which all B cells lack CCR7 expression (B:Ccr7−/−),
CD45.1+ Rag2−/− mice were irradiated and reconstituted with
mixed BM comprising 75% CD45.1+ μMT and 25% CD45.2+ CCR7-
deficient BM. Control chimeras were CD45.1+ Rag2−/− mice ir-
radiated and reconstituted with mixed BM comprising 75%
CD45.1+ μMT and 25% CD45.2+ C57BL/6 BM.
Flow cytometry
LN samples were pressed through a 40-µm mesh before anti-
body staining in PBS/2% FCS. Lung samples were minced with
scissors then forced through a 70-µm mesh before antibody
staining. For detection of transcription factors and other intra-
cellular proteins, cells were fixed and permeabilized with Foxp3
fix/perm kit (eBioscience). Antibodies were from eBioscience,
BioLegend, or BD Biosciences, unless indicated otherwise, and
directed against CD4 (Rm4-5, GK1.5), B220 (RA3-6B2), Foxp3
(FJK-16s), T-bet (eBio4B10), CD19 (6D5), CD138 (281–2), CXCR5
(L138D7), Bcl6 (K112-91), CXCR3 (CXCR3-173), Ki67 (Sol1a1),
CXCR4 (L276F12), CD8 (145-2C11), CD11b (M1/70), EpCAM
(G8.8), PDGFRα (APA5), CD31 (MEC13.3), ICAM (YN1/1.7.4),
CD45 (30-F11), CD86 (GL-1), GL7 (GL7), CD95 (Jo2), MHC II (M5/
114.15.2), PD-1 (J43), Sca1 (D7), CD44 (IM7), CD90.2 (30-H12), IL-
7Rα (A7R34), IgG1 (A85-1), NP (N-5070-1; Biosearch Technolo-
gies), and human CD2 (RPA-2.10). Dead cells were excludedwith
fixable viability dyes (e780; eBioscience; and Zombie UV;
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BioLegend) or DAPI (Sigma). HEL-binding B cells were detected
as described previously (Brink et al., 2015).
Microscopy
Lungs were inflated with a 1:1 mix of periodate-lysine-parafor-
maldehyde with optimal cutting temperature compound and
fixed in periodate-lysine-paraformaldehyde for 5 h at 4°C and
then embedded in optimal cutting temperature medium. Lung
sections were cut at 30 µm, air dried overnight, and then stored
at −20°C. Prior to staining, lung sections were further dried for
2 h at 37°C, rehydrated, and blocked with 1% BSA (Sigma) and,
where appropriate, 5% goat serum (Sigma). For detection of
biotinylated antibodies, endogenous biotin was blocked (Vec-
torlabs). Sections were stained with B220-488 or -BV421 (RA3-
6B2; BioLegend), CD3-APC (17A2; eBioscience), CD31-594 or
-biotin (MEC13.3; BioLegend), CD35-biotin (8C12; BD Bio-
sciences), Ki67-FITC (eBioscience), and/or biotinylated anti-
hCD2 (RPA-2.10; eBioscience). Biotinylated antibodies were de-
tected with streptavidin-BV421 (BioLegend) or -647 (eBio-
science). Images were acquired using a Zeiss LSM780 harboring
405-, 488-, 561-, and 633-nm lasers. Channels were collected in
separate frames using 20×/0.50 NA air or 40×/1.40 NA oil len-
ses. Images were analyzed and compiled using Fiji (National
Institutes of Health) software. For analysis of medLN GC
structure, 10× tiled images of whole LNs were collected, and GC
size was determined by manually outlining the GC area (as in-
dicated by lack of IgD staining) and measuring the area (in
square micrometers) using Fiji software. For analysis of the DZ
area, the Ki67 stain was converted to a binary image after
thresholding and the proportion of the manually-defined GC
area that was Ki67+ was calculated using Fiji software. Values
were calculated for individual GCs in each section and averaged
across all mice in each group.
Whole-lung RNA analysis
Whole lungs or single lobes were homogenized in 2 ml or 1 ml
Trizol (Life Technologies), respectively. RNA from 1 ml was
extracted as per manufacturer’s instructions, keeping volumes
strictly equal between samples. Analysis of mRNA expression
was determined using equal volumes of starting material and
TaqMan primer probes (Applied Biosystems) using the RNA-to-
Ct kit (Applied Biosystems), Luna Universal Probe qPCR kit
(New England BioLabs), or TaqMan Universal PCR kit (Applied
Biosystems) following cDNA generation with random hexamers
(ThermoFisher). Ct values were arbitrarily converted to copy
number per whole lung or lobe using the equation 105 = 2(Ct-17),
wherein a Ct value of 17 is equivalent to 105 copies.
Cell sorting and RNA analysis
Lung stromal cells were isolated as previously described (Denton
et al., 2014) and stained for EpCAM (G8.8), CD31 (MEC13.3), CD45
(30-F11), PDGFRα (APA5), and ICAM (YN1/1.7.4), sorted on a
BD Influx and RNA extracted using the RNEasy Micro kit
(Qiagen). Quantitative real time PCR was performed for Cxcl13
(Mm0044533_m1),Ccl19 (Mm00839967_g1), Ifnb1 (Mm00439552_s1)
and Mx1 (Mm00487796_m1) using the indicated TaqMan
primer probes and the RNA-to-Ct kit (Applied Biosystems)
and expression normalized to Gapdh (Mm99999915_g1) or
Hprt (Mm03024075_m1).
Lung fibroblast cell culture
Lung stromal cells were isolated by digestion and cultured on
tissue culture–treated plates at 37°C 5% CO2 in RPMI supple-
mented with 10% FCS, penicillin, and streptomycin. Non-
adherent cells were removed by manual disruption 24 and
72 h after plating, thus maintaining adherent fibroblasts in
culture. Prior to stimulation, fibroblasts were washed with
RPMI/10% FCS and then stimulated with IL-1α (200 ng/ml; Pe-
protech), IL-1β (200 ng/ml; Peprotech), IL-6 (200 ng/ml; Pe-
protech), IFNα (1,000 U/ml; pbl assay sciences), IFNβ (1.6 × 104
U/ml; Bayer), G-CSF (200 ng/ml; Peprotech), or TNF (200 ng/
ml; Peprotech) for 6 h in media lacking antibiotics. RNA was
extracted using the Trizol method and transcripts quantified as
described previously (Denton et al., 2014), with Cxcl13 expression
determined relative to Gapdh or Hprt and then normalized to
unstimulated cells.
Microarray analysis
For the analysis of whole-lung transcriptome over the course of
IAV infection, publicly available Robust Multiarray Averaging
(RMA)–normalized data were downloaded from the ArrayEx-
press database (accession no. E-MTAB-764). This dataset is a
time course of the transcriptomes of whole lungs in C57BL/6
mice infected with IAV (strain A/Puerto Rico/8/1934 H1N1;
Pommerenke et al., 2012). The heat map was generated using
probes matching our curated gene list. Each probe was sum-
marized using a mean difference from mock-infected samples.
In brief, we first corrected RMA expression values from each
probe using the mean expression in mock-infected samples.
Second, biological replicates of each time point were averaged
using means. For Ifng and Il1a, there were two matching probes,
which behaved similarly; for clarity only one was plotted. The
analysis was performed in RStudio (version 1.0.153)/R version
3.4.1; https://www.R-project.org/) using the following packages:
Bioconductor (Biobase version 2.36.2), ArrayExpress (1.36.1),
pheatmap (1.0.9), and gridSVG (1.6–0), with Bioconductor’s
microarray annotation package mgug4122a.db (3.2.3).
For analysis of global gene expression changes in Ifnar1−/− and
WT animals, raw data were downloaded from the Gene Ex-
pression Omnibus database (accession no. GSE48890). Agilent
data were imported in R, using read.maimages from the limma
package (3.32.10) and normalized using the variance stabiliza-
tion normalization. Sample annotation data (in sdrf format)
were downloaded from the corresponding ArrayExpress record.
This experiment measured whole-lung transcriptomes at days 1,
3, and 4 after i.n. infectionwith either r1918 or VN1203 influenza
virus in both WT and Ifnar1−/− animals (Cilloniz et al., 2010).
Limma was performed using the dye-swap pairs for each sam-
ple, with the following contrasts: difference day 3 = (Ifnar1−/− day
3 − Ifnar1−/− day 1) − (WT day 3 − WT day 1) and difference day
4 = (Ifnar1−/− day 4 − Ifnar1−/− day 3) − (WT day 4 − WT day 3).
This seeks to find genes that are significantly different between
Ifnar1−/− and WT over time, i.e., genes where the response is lost
or gained by the absence of IFNAR1. P values from F tests on
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these linear models were used after Benjamini–Hochberg mul-
tiple correction testing. We did not separate r1918 from VN1203
for this analysis. We used the “HALLMARK_INTERFER-
ON_ALPHA_RESPONSE” gene set defined by the molecular
signatures database (http://software.broadinstitute.org/gsea/
msigdb/cards/HALLMARK_INTERFERON_ALPHA_RESPONSE.
html). This is a computationally generated gene set based on
concordance between various IFN stimulation gene expression
experiments. To define chemokines, we used two gene ontology
(GO) terms: GO:0048020 = CCR chemokine receptor binding
and GO:0045236 = CXCR chemokine receptor binding. These
were mapped to gene symbols using Bioconductor annotation
package org.Mm.eg.db (3.4.1). Cxcl13 expression at day 3 used
normalized data from a single dye swap (day 3 postinfection
cDNA labeled with Cy5, uninfected cDNA labeled with Cy3).
Statistical analysis
Single comparisons were analyzed using the nonparametric
Mann–Whitney U test. Multiple comparisons were performed
using ANOVA with Bonferroni multiple testing correction. All
statistical analyses were performed with GraphPad Prism, un-
less otherwise indicated.
Online supplemental material
Fig. S1 shows the expression of GL-7 and CD95, the CD45i.v.
labeling of pulmonary GC B cells, and the presence of pulmonary
plasma cells. Fig. S2 shows the role of Tfh cells and B cell–
expressed CXCR3 in B cell migration to the lung 6 d after IAV
infection. Fig. S3 is the gating strategy for identifying stromal
cell populations in the lung. Fig. S4 shows B cell trafficking, lung
GC formation, and enhanced viral load in IFNAR1-deficient mice.
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